COVINGTON & BURLING LLP for ZYMERGEN INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG New | — |
Medical/Disease Research/Clinical Labs MED
Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG New | — |
Science/Technology SCI
Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| SVF EXCALIBUR (CAYMAN) LIMITED | Cayman Islands | Cayman Islands | 24.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.